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Background
Medicines are of major relevance for the treatment of
cancer. They appear to be among high-cost medicines;
however, their prices are not generally known. In this
context, the study aims to survey the prices of oncology
medicines in European countries, Australia and New
Zealand and explore differences across the countries.
Methods
Ex-factory prices per unit as for June 2013 of 31 oncology
medicines in 16 European countries, Australia and New
Zealand were surveyed and compared. Medicine price
data for the 16 European countries were provided by the
Pharma Price Information (PPI) service, and Australian
and New Zealand medicine price data were retrieved
from the respective Pharmaceutical Schedules. Official
undiscounted list prices were taken into consideration.
Price data refer mainly but not exclusively to the hospital
sector and to medicines funded by the State.
Results
Data availability was higher in the European countries
compared with Australia and particularly New Zealand.
Oncology medicines are highly priced. None of the
medicines surveyed had a unit price below EUR 10 in
the 18 surveyed countries. Five medicines had an aver-
age unit ex-factory price between EUR 250 and EUR
1,000, and seven medicines had an average unit price
above EUR 1,000.
The difference between the price of a medicine in the
highest-priced country and the one in the lowest priced
country varied between 28% and 233% except for one
medicine with generics on the market (388%). A few medi-
cines had lower outliers (particularly Greek and UK prices)
and upper outliers (particularly prices in Switzerland,
Germany and Sweden). Overall, Greek prices ranked at a
low level, whereas Sweden, Switzerland and Germany
showed price data in comparably high ranges.
No pattern was identified as to whether prices in
Australia and New Zealand were high or low compared
with European countries.
Conclusions
While no relevant price differences of Australia and
New Zealand in comparison with European countries
were found, funding of oncology medicines appeared to
be more restrictive in these two countries, and access to
be granted at a later stage. However, these official list
prices do not include discounts and similar arrange-
ments that are in place for several of the surveyed medi-
cines in a number of countries.
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